Published in J Clin Neurol on April 04, 2013
Neuroimmunity dynamics and the development of therapeutic strategies for amyotrophic lateral sclerosis. Front Cell Neurosci (2013) 0.90
F Wave Study in Amyotrophic Lateral Sclerosis: Assessment of Segmental Motoneuronal Dysfunction. Chin Med J (Engl) (2015) 0.84
Modeling ALS with motor neurons derived from human induced pluripotent stem cells. Nat Neurosci (2016) 0.83
Peripheral challenge with a viral mimic upregulates expression of the complement genes in the hippocampus. J Neuroimmunol (2015) 0.81
Identifying the primary site of pathogenesis in amyotrophic lateral sclerosis - vulnerability of lower motor neurons to proximal excitotoxicity. Dis Model Mech (2015) 0.77
A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression. Neurology (2016) 0.77
Calretinin and Neuropeptide Y interneurons are differentially altered in the motor cortex of the SOD1(G93A) mouse model of ALS. Sci Rep (2017) 0.75
Cortical synaptic and dendritic spine abnormalities in a presymptomatic TDP-43 model of amyotrophic lateral sclerosis. Sci Rep (2016) 0.75
Dissociation of Structural and Functional Integrities of the Motor System in Amyotrophic Lateral Sclerosis and Behavioral-Variant Frontotemporal Dementia. J Clin Neurol (2016) 0.75
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science (2008) 14.09
Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science (2009) 13.45
Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science (2009) 12.99
TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun (2006) 10.69
Excitatory amino acid transmitters. Annu Rev Pharmacol Toxicol (1981) 6.70
Amyotrophic lateral sclerosis. Lancet (2011) 5.86
TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol (2008) 5.58
Rethinking ALS: the FUS about TDP-43. Cell (2009) 4.71
Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol (2007) 3.96
Transcranial magnetic stimulation: a primer. Neuron (2007) 3.77
Transcranial magnetic stimulation and the human brain. Nature (2000) 3.14
Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci (1990) 2.98
Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve (1998) 2.61
TMS and drugs. Clin Neurophysiol (2004) 2.52
Differential effects on motorcortical inhibition induced by blockade of GABA uptake in humans. J Physiol (1999) 2.52
ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology (2009) 2.47
Dissociated small hand muscle involvement in amyotrophic lateral sclerosis detected by motor unit number estimates. Muscle Nerve (1999) 2.03
Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain (2008) 1.94
Electrical synapses define networks of neocortical GABAergic neurons. Trends Neurosci (2005) 1.85
Glutamate transporters in neurologic disease. Arch Neurol (2001) 1.80
TDP-43: a novel neurodegenerative proteinopathy. Curr Opin Neurobiol (2007) 1.73
Increased persistent sodium current determines cortical hyperexcitability in a genetic model of amyotrophic lateral sclerosis. Exp Neurol (2008) 1.71
Mechanism of the silent period following transcranial magnetic stimulation. Evidence from epidural recordings. Exp Brain Res (1999) 1.68
Impaired motor cortex inhibition in patients with amyotrophic lateral sclerosis. Evidence from paired transcranial magnetic stimulation. Neurology (1997) 1.67
The role of monoamine metabolism in oxidative glutamate toxicity. J Neurosci (1996) 1.66
Decreased motor cortex γ-aminobutyric acid in amyotrophic lateral sclerosis. Neurology (2012) 1.64
Amyotrophic lateral sclerosis-Evolutionary and other perspectives. Muscle Nerve (2009) 1.56
Cortical excitability testing distinguishes Kennedy's disease from amyotrophic lateral sclerosis. Clin Neurophysiol (2008) 1.54
The split hand syndrome in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2011) 1.50
Does the motor cortex influence denervation in ALS? EMG studies of muscles with both contralateral and bilateral corticospinal innervation. Clin Neurophysiol (2010) 1.49
Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. Clin Neurophysiol (2012) 1.49
Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain (2006) 1.47
Lower motor neuron involvement examined by quantitative electromyography in amyotrophic lateral sclerosis. Clin Neurophysiol (2010) 1.47
Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve (2002) 1.44
Corticomotor threshold is reduced in early sporadic amyotrophic lateral sclerosis. Muscle Nerve (1997) 1.34
Altered axonal excitability properties in amyotrophic lateral sclerosis: impaired potassium channel function related to disease stage. Brain (2006) 1.33
Motor neuron dysfunction in frontotemporal dementia. Brain (2011) 1.31
Firing pattern of fasciculations in ALS: evidence for axonal and neuronal origin. Neurology (2008) 1.28
Age-related loss of the GABA synthetic enzyme glutamic acid decarboxylase in rat primary auditory cortex. Neuroscience (2005) 1.26
Distinct cerebral lesions in sporadic and 'D90A' SOD1 ALS: studies with [11C]flumazenil PET. Brain (2005) 1.24
Axonal excitability properties in amyotrophic lateral sclerosis. Clin Neurophysiol (2006) 1.22
Patterns of neuronal degeneration in the motor cortex of amyotrophic lateral sclerosis patients. Acta Neuropathol (1993) 1.22
Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis? Amyotroph Lateral Scler (2012) 1.18
Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. Adv Neurol (1995) 1.17
On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Antioxid Redox Signal (2006) 1.17
Assessment of cortical excitability using threshold tracking techniques. Muscle Nerve (2006) 1.17
Dissociated small hand muscle atrophy in amyotrophic lateral sclerosis: frequency, extent, and specificity. Muscle Nerve (2008) 1.16
The "split hand syndrome". Muscle Nerve (2000) 1.14
Extramotor involvement in ALS: PET studies with the GABA(A) ligand [(11)C]flumazenil. Brain (2000) 1.13
Amyotrophic lateral sclerosis (ALS): a phylogenetic disease of the corticomotoneuron? Muscle Nerve (1992) 1.11
Distribution of GABAA receptor mRNA in the motor cortex of ALS patients. J Neuropathol Exp Neurol (2003) 1.08
Diagnosis of amyotrophic lateral sclerosis. J Neurol Sci (1998) 1.08
Neocortical inhibitory system. Folia Biol (Praha) (2009) 1.07
Strength-duration properties of sensory and motor axons in amyotrophic lateral sclerosis. Brain (1998) 1.06
Abnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2007) 1.05
Why are upper motor neuron signs difficult to elicit in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry (2012) 1.03
Amyotrophic lateral sclerosis: lower motor neuron disease spreading to upper motor neurons. Muscle Nerve (1993) 1.01
Preclinical and subclinical events in motor neuron disease. J Neurol Neurosurg Psychiatry (1988) 1.01
Differences in excitability properties of FDI and ADM motor axons. Muscle Nerve (2009) 0.99
Fatigue and activity dependent changes in axonal excitability in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2007) 0.98
Cramps, muscle pain, and fasciculations: not always benign? Neurology (2004) 0.97
Double cortical stimulation in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (1996) 0.93
Excitotoxic cell death dependent on inhibitory receptor activation. Exp Neurol (1999) 0.92
Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2012) 0.91
Changes in motor cortex inhibition over time in patients with amyotrophic lateral sclerosis. J Neurol (2002) 0.91
Different mechanisms contribute to motor cortex hyperexcitability in amyotrophic lateral sclerosis. Clin Neurophysiol (2002) 0.91
How do the RNA-binding proteins TDP-43 and FUS relate to amyotrophic lateral sclerosis and frontotemporal degeneration, and to each other? Curr Opin Neurol (2012) 0.89
Na(+)-Ca2+ exchanger mediates Ca2+ influx during anoxia in mammalian central nervous system white matter. Ann Neurol (1991) 0.89
Distal excitability changes in motor axons in amyotrophic lateral sclerosis. Clin Neurophysiol (2006) 0.88
Recurrent inhibition is decreased in patients with amyotrophic lateral sclerosis. Neurology (1994) 0.87
Pharmacologic reversal of cortical hyperexcitability in patients with ALS. Neurology (2000) 0.85
Cortical excitability in amyotrophic lateral sclerosis: a clue to pathogenesis. Can J Neurol Sci (1993) 0.85
Effects of riluzole on cortical excitability in patients with amyotrophic lateral sclerosis. Ann Neurol (2001) 0.84
Neurophysiological features of fasciculation potentials evoked by transcranial magnetic stimulation in amyotrophic lateral sclerosis. J Neurol (2000) 0.84
Ultrastructure of excitotoxic neuronal death in murine cortical culture. Brain Res (1995) 0.83
Section I: Alphabetic list of terms with definitions. Muscle Nerve (2001) 0.82
Frontotemporal lobar degeneration with motor neuron disease: a clinical and pathological spectrum. Arch Neurol (2006) 0.82
Clinical electrophysiology of the upper and lower motor neuron in amyotrophic lateral sclerosis. Semin Neurol (2001) 0.81
Hyperexcitability, persistent Na+ conductances and neurodegeneration in amyotrophic lateral sclerosis. Exp Neurol (2009) 0.80
Electrophysiologic evaluation of upper motor neuron involvement in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord (2001) 0.80
Diazepam, given postischemia, protects selectively vulnerable neurons in the rat hippocampus and striatum. J Neurosci (1995) 0.79
Early diagnosis of ALS/MND. J Neurol Sci (1998) 0.78
Split-hand plus sign in ALS: differential involvement of the flexor pollicis longus and intrinsic hand muscles. Amyotroph Lateral Scler Frontotemporal Degener (2012) 0.78
Ultrasonographic assessment of the prevalence of fasciculations in lesions of the peripheral nervous system. J Neuroimaging (1997) 0.77
Dissociated small hand muscle atrophy in aging: the 'senile hand' is a split hand. Eur J Neurol (2006) 0.77
H-reflex changes in the course of amyotrophic lateral sclerosis. Electroencephalogr Clin Neurophysiol (1997) 0.76
Motor neuron disease. Studies of the corticospinal excitation of single motor neurons by magnetic brain stimulation. Brain (1995) 0.76
Excitatory amino acids, free radicals and the pathogenesis of motor neuron disease. Neuropathol Appl Neurobiol (1994) 0.76
Why is ALS so excited? Clin Neurophysiol (2011) 0.76
Fasciculation potentials in foot and leg muscles of healthy young adults. Electroencephalogr Clin Neurophysiol (1994) 0.76
The onset of ALS? Clin Neurophysiol (2010) 0.76
Amyotrophic lateral sclerosis. Lancet (2011) 5.86
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol (2013) 2.52
Guillain-Barré syndrome: an update. J Clin Neurosci (2009) 2.46
Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol (2009) 2.20
Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol (2011) 2.08
Botulinum toxin modulates cortical maladaptation in post-stroke spasticity. Muscle Nerve (2013) 2.00
Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain (2008) 1.94
Isolated bulbar phenotype of amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2011) 1.75
The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis. Hum Mol Genet (2010) 1.73
Segmental facial anhidrosis and tonic pupils with preserved deep tendon reflexes: a novel autonomic neuropathy. J Neuroophthalmol (2005) 1.63
Cortical excitability distinguishes ALS from mimic disorders. Clin Neurophysiol (2011) 1.59
Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Arch Neurol (2011) 1.55
Cortical excitability testing distinguishes Kennedy's disease from amyotrophic lateral sclerosis. Clin Neurophysiol (2008) 1.54
Split-hand index for the diagnosis of amyotrophic lateral sclerosis. Clin Neurophysiol (2012) 1.52
Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain (2009) 1.50
Changes in human sensory axonal excitability induced by an ischaemic insult. Clin Neurophysiol (2008) 1.49
Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. Clin Neurophysiol (2012) 1.49
Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain (2006) 1.47
Corticomotoneuronal function in asymptomatic SOD-1 mutation carriers. Clin Neurophysiol (2010) 1.47
FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J Neurol Neurosurg Psychiatry (2009) 1.44
Riluzole: a glimmer of hope in the treatment of motor neurone disease. Med J Aust (2005) 1.42
Regional differences in ulnar nerve excitability may predispose to the development of entrapment neuropathy. Clin Neurophysiol (2010) 1.41
Differentiating patterns of oligoclonal banding in the cerebrospinal fluid improves diagnostic utility for multiple sclerosis. Pathology (2012) 1.41
Scurvy and stroke - is there an association? Med J Aust (2010) 1.40
Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve (2005) 1.37
Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol (2009) 1.37
Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin (2014) 1.36
Neurotoxic marine poisoning. Lancet Neurol (2005) 1.33
Motor neuron dysfunction in frontotemporal dementia. Brain (2011) 1.31
Uremic neuropathy: clinical features and new pathophysiological insights. Muscle Nerve (2007) 1.30
Axonal ion channels from bench to bedside: a translational neuroscience perspective. Prog Neurobiol (2009) 1.27
Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist (2011) 1.22
Axonal excitability properties in amyotrophic lateral sclerosis. Clin Neurophysiol (2006) 1.22
Pathophysiology of neurodegeneration in familial amyotrophic lateral sclerosis. Curr Mol Med (2009) 1.19
Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis? Amyotroph Lateral Scler (2012) 1.18
Fatigue in multiple sclerosis: mechanisms and management. Clin Neurophysiol (2010) 1.18
Altered nerve excitability properties in established diabetic neuropathy. Brain (2005) 1.17
Assessment of cortical excitability using threshold tracking techniques. Muscle Nerve (2006) 1.17
Grey and white matter changes across the amyotrophic lateral sclerosis-frontotemporal dementia continuum. PLoS One (2012) 1.15
Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights. J Neurol Neurosurg Psychiatry (2012) 1.14
Activity-dependent excitability changes suggest Na+/K+ pump dysfunction in diabetic neuropathy. Brain (2008) 1.10
FOSMN syndrome: novel insight into disease pathophysiology. Neurology (2012) 1.10
How common are behavioural changes in amyotrophic lateral sclerosis? Amyotroph Lateral Scler (2010) 1.09
Amyotrophic lateral sclerosis and frontotemporal dementia: A behavioural and cognitive continuum. Amyotroph Lateral Scler (2012) 1.08
Abnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2007) 1.05
Changes in human sensory axonal excitability induced by focal nerve compression. J Physiol (2010) 1.04
Altered motor nerve excitability in end-stage kidney disease. Brain (2005) 1.02
Oxaliplatin and axonal Na+ channel function in vivo. Clin Cancer Res (2006) 1.00
Nerve function and dysfunction in acute intermittent porphyria. Brain (2008) 1.00
Engaging in patient decision-making in multidisciplinary care for amyotrophic lateral sclerosis: the views of health professionals. Patient Prefer Adherence (2012) 1.00
Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer (2012) 0.98
Fatigue and activity dependent changes in axonal excitability in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2007) 0.98
Treatment of proximal upper limb tremor with botulinum toxin therapy. Mov Disord (2013) 0.97
INSPIRATIonAL--INSPIRAtory muscle training in amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2009) 0.96
Upregulation of persistent sodium conductances in familial ALS. J Neurol Neurosurg Psychiatry (2009) 0.95
Corticomotoneuronal function and hyperexcitability in acquired neuromyotonia. Brain (2010) 0.95
Quantifying disease progression in amyotrophic lateral sclerosis. Ann Neurol (2014) 0.94
Axonal changes in spinal cord injured patients distal to the site of injury. Brain (2007) 0.94
Threshold behaviour of human axons explored using subthreshold perturbations to membrane potential. J Physiol (2008) 0.94
Neurological complications of chronic kidney disease. Nat Rev Neurol (2009) 0.93
Has potassium been prematurely discarded as a contributing factor to the development of uraemic neuropathy? Nephrol Dial Transplant (2004) 0.93
Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain (2013) 0.92
Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity. PLoS One (2011) 0.92
Pathophysiological insights into ALS with C9ORF72 expansions. J Neurol Neurosurg Psychiatry (2013) 0.92
Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. Ann Neurol (2014) 0.91
Neurophysiological index as a biomarker for ALS progression: validity of mixed effects models. Amyotroph Lateral Scler (2011) 0.91
Assessment of disease progression in motor neuron disease. Lancet Neurol (2005) 0.91
Cortical atrophy in ALS is critically associated with neuropsychiatric and cognitive changes. Neurology (2013) 0.90
Congenital myasthenic syndromes. J Clin Neurosci (2008) 0.90
Assessing the accuracy of a combination of clinical tests for identifying carpal tunnel syndrome. J Clin Neurosci (2009) 0.90
The Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform. PLoS One (2013) 0.90
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. PLoS One (2013) 0.89
The case of a 48 year-old woman with bizarre and complex delusions. Nat Rev Neurol (2010) 0.89
Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy. J Pediatr (2012) 0.89
Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. Muscle Nerve (2010) 0.88
Assessment of nerve excitability in toxic and metabolic neuropathies. J Peripher Nerv Syst (2008) 0.88
Puffer fish poisoning: a potentially life-threatening condition. Med J Aust (2002) 0.88
Riluzole therapy for motor neurone disease: an early Australian experience (1996-2002). J Clin Neurosci (2006) 0.87
The effects of alterations in conditioning stimulus intensity on short interval intracortical inhibition. Brain Res (2009) 0.87
Predicting a positive response to intravenous immunoglobulin in isolated lower motor neuron syndromes. PLoS One (2011) 0.87
Dual reinnervation of biceps muscle after side-to-side anastomosis of an intact median nerve and a damaged musculocutaneous nerve. J Neurosurg (2013) 0.86
Defining the mechanisms that underlie cortical hyperexcitability in amyotrophic lateral sclerosis. Exp Neurol (2009) 0.86
The Genetics of Spinal Muscular Atrophy: Progress and Challenges. Neurotherapeutics (2015) 0.86
Neuropsychiatric changes precede classic motor symptoms in ALS and do not affect survival. Neurology (2013) 0.85